在晚期前列腺癌治疗中,LX1双重向AR变体和AKR1C3
Shu Ning1, Cameron M Armstrong1, Enming Xing2
1Department of Urologic Surgery, University of California Davis, Davis, California.
Cancer research
|August 1, 2024
概括
一种新的化合物LX1针对雄激素受体变体和AKR1C3来克服晚期前列腺癌的抗性. 它在组合疗法中表现有前途,减少瘤生长并改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 分子生物学分子生物学
背景情况:
- 先进的前列腺癌往往会对标准的雄激素受体 (AR) 向疗法产生抗性.
- 耐药性的关键驱动因素包括AR-V7等AR变种和AKR1C3.3.等类固醇酶.
研究的目的:
- 设计和合成针对AR/AR变体和AKR1C3通路的新型化合物 (LX化合物).
- 在抗性前列腺癌的临床前模型中评估这些化合物的疗效.
主要方法:
- 分子对接和体外研究,以评估AKR1C3.3.的结合和抑制.
- 对AR/AR-V7表达和信号的评估.
- 活体酶试验和体外细胞生长抑制试验.
- 在使用前列腺癌异种移植模型的体内研究.
主要成果:
- LX化合物抑制AKR1C3的酶活性,并减少AR/AR-V7的表达.
- LX1证明了对抗多个抗雄激素耐药的细胞的有效性,并抑制了的转化.
- LX1与抗雄激素和税具有协同作用,在体内显著降低瘤体积和PSA水平.
- 在异种移植模型中,LX1克服了对恩扎拉胺的耐药性,并抑制了结合恩扎拉胺的瘤生长.
结论:
- LX1表现出双重的作用机制,针对AR信号和内丸激素的产生.
- 对于晚期前列腺癌来说,LX1显示出作为一种有价值的治疗剂的潜力,特别是在克服耐药性方面.
- 使用LX1和标准治疗的组合疗法在抗性前列腺癌中提供了增强的疗效.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K